SCHEMBL6985131

SCHEMBL6985131

O=C(O)C1C=Nc2c(c(O)c(O)c3cccnc23)C1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.37
L3MBTL1 Q9Y468 4/20 0.37
EGLN1 Q9GZT9 3/20 0.37
KDM4A O75164 2/20 0.37
KDM6B O15054 1/20 0.37
KDM6A O15550 1/20 0.37
TET3 O43151 1/20 0.37
KDM4B O94953 1/20 0.37
KDM5C P41229 1/20 0.37
KDM4D Q6B0I6 1/20 0.37
TET2 Q6N021 1/20 0.37
ALKBH5 Q6P6C2 1/20 0.37
TET1 Q8NFU7 1/20 0.37
FTO Q9C0B1 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
KDM2A Q9Y2K7 1/20 0.37
KDM3A Q9Y4C1 1/20 0.37
ALDH1A1 P00352 6/20 0.34
RPS6KA3 P51812 1/20 0.33
GLO1 Q04760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL967454 0.79 L3MBTL1 (0.39) KDM4EL3MBTL1EGLN1KDM4AKDM6B
SCHEMBL5819956 0.76 DAO (0.36) KDM4EL3MBTL1EGLN1KDM4AKDM6B
SCHEMBL6987201 0.75 CCR1 (0.40) KDM4EL3MBTL1ALDH1A1TP53MAPT
SCHEMBL6975182 0.75 L3MBTL1 (0.40) L3MBTL1ALDH1A1MEN1KMT2AMAPT
SCHEMBL6986566 0.75 L3MBTL1 (0.39) KDM4EL3MBTL1EGLN1KDM4AKDM6B
SCHEMBL6981101 0.75 L3MBTL1 (0.43) KDM4EL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL1509598 0.71 LMNA (0.43) KDM4EL3MBTL1EGLN1TET2TET1
SCHEMBL1509799 0.71 SLC40A1 (0.37) KDM4EL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL6982865 0.68 HAVCR2 (0.30)
SCHEMBL5566400 0.66 KMT2A (0.35) KDM4EL3MBTL1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 KDM4E 162/4885L3MBTL1 2168/4885EGLN1 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.